ANI Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

ANI Pharmaceuticals Il CEO è Nikhil Lalwani, nominato in Sep2020, e ha un mandato di 4.17 anni. la retribuzione annua totale è $ 8.08M, composta da 9.5% di stipendio e 90.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.91% delle azioni della società, per un valore di € 21.04M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3 anni e 4.2 anni.

Informazioni chiave

Nikhil Lalwani

Amministratore delegato

US$8.1m

Compenso totale

Percentuale dello stipendio del CEO	9.5%
Mandato del CEO	4.2yrs
Proprietà del CEO	1.9%
Durata media del management	3yrs
Durata media del Consiglio di amministrazione	4.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Nikhil Lalwani rispetto agli utili di ANI Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$9m
Jun 30 2024	n/a	n/a	US$24m
Mar 31 2024	n/a	n/a	US$31m
Dec 31 2023	US$8m	US$764k	US$15m
Sep 30 2023	n/a	n/a	US$10m
Jun 30 2023	n/a	n/a	-US$8m
Mar 31 2023	n/a	n/a	-US$28m
Dec 31 2022	US$5m	US$737k	-US$50m
Sep 30 2022	n/a	n/a	-US$69m
Jun 30 2022	n/a	n/a	-US$65m
Mar 31 2022	n/a	n/a	-US$63m
Dec 31 2021	US$7m	US$715k	-US$43m
Sep 30 2021	n/a	n/a	-US$22m
Jun 30 2021	n/a	n/a	-US$17m
Mar 31 2021	n/a	n/a	-US$15m
Dec 31 2020	US$4m	US$199k	-US$23m

Compensazione vs Mercato: La retribuzione totale di Nikhil ($USD 8.08M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 1.48M ).

Compensazione vs guadagni: La retribuzione di Nikhil è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Nikhil Lalwani (46 yo)

4.2yrs

Mandato

US$8,078,353

Compensazione

Mr. Nikhil Lalwani served as a Director of Association for Accessible Medicines. He served as the Chief Executive Officer of InvaGen Pharmaceuticals, Inc. since October 24, 2016. Mr. Lalwani is a seasoned...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Nikhil Lalwani	President	4.2yrs	US$8.08m	1.91% € 21.0m
Stephen Carey	Senior VP of Finance & CFO	8.5yrs	US$2.58m	0.83% € 9.1m
Chad Gassert	Senior Vice President of Corporate Development & Strategy	3yrs	US$1.90m	1.24% € 13.7m
Christopher Mutz	Senior Vp & Head of Rare Disease	3.8yrs	US$1.91m	0.39% € 4.3m
Ori Gutwerg	Senior Vice President of Generics	3.8yrs	US$1.94m	0.40% € 4.3m
Muthusamy Shanmugam	Head of R&D	3yrs	Nessun dato	0.26% € 2.9m
James Marken	Senior Vice President of Operations	8.5yrs	US$1.43m	0.60% € 6.6m
Elizabeth Powell	Chief Compliance Officer & Head of Legal of Rare Disease	2.8yrs	Nessun dato	Nessun dato
Meredith Cook	Senior VP	2.3yrs	Nessun dato	0.29% € 3.2m
Krista Davis	Senior VP & Chief Human Resources Officer	2.2yrs	Nessun dato	0.26% € 2.8m
Mary Pao	Chief Medical Officer	2.8yrs	Nessun dato	Nessun dato
Thomas Rowland	Senior VP & Head of Established Brands	3yrs	Nessun dato	0.17% € 1.9m

3.0yrs

Durata media

51.5yo

Età media

Gestione esperta: Il team dirigenziale di BSFA è considerato esperto (durata media dell'incarico 3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Nikhil Lalwani	President	4.2yrs	US$8.08m	1.91% € 21.0m
Muthusamy Shanmugam	Head of R&D	3yrs	Nessun dato	0.26% € 2.9m
Patrick Walsh	Independent Chairman	6.5yrs	US$422.21k	0.38% € 4.2m
Antonio Pera	Independent Director	4.3yrs	US$393.25k	0.16% € 1.7m
Thomas Haughey	Independent Director	6.5yrs	US$412.21k	0.26% € 2.9m
Jeanne Thoma	Independent Director	4.3yrs	US$395.75k	0.21% € 2.3m
Renee Tannenbaum	Independent Director	2.7yrs	US$392.37k	0.12% € 1.3m
Matthew Leonard	Independent Director	1.3yrs	US$470.76k	0.061% € 675.0k

4.2yrs

Durata media

61.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BSFA sono considerati esperti (durata media dell'incarico 4.2 anni).

ANI Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Senior Vp & Head of Rare Disease recently sold €356k worth of stock

Senior VP of Finance & CFO recently sold €292k worth of stock

President recently sold €1.0m worth of stock

ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Independent Director recently sold €420k worth of stock

Head of Rare Disease recently sold €148k worth of stock

Recent updates

Senior Vp & Head of Rare Disease recently sold €356k worth of stock

Third quarter 2024 earnings released: US$1.27 loss per share (vs US$0.46 profit in 3Q 2023)

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024

ANI Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Estradiol Gel, 0.06%

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.

Alimera Sciences, Inc. Takes Legal Action Against ANI Pharmaceuticals, Inc. to Enforce Merger Agreement

Second quarter 2024 earnings released: US$0.14 loss per share (vs US$0.30 profit in 2Q 2023)

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024

ANI Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of L-Glutamine Oral Powder

ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 3000E Value Index

ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) signed a definitive agreement to acquire Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million.

Senior VP of Finance & CFO recently sold €292k worth of stock

President recently sold €1.0m worth of stock

ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$0.93 (vs US$0.056 in 1Q 2023)

ANI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 10, 2024

ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension

ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP

Independent Director recently sold €420k worth of stock

Full year 2023 earnings released: EPS: US$0.95 (vs US$3.05 loss in FY 2022)

ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

ANI Pharmaceuticals, Inc. to Report Second Half, 2023 Results on Feb 29, 2024

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP

Head of Rare Disease recently sold €148k worth of stock

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: US$0.51 (vs US$0.55 loss in 3Q 2022)

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

ANI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Ani Pharmaceuticals Announces Fda Approval and Commercial Availability of New 1-Ml Vial Size of Purified Cortrophin®? Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares

Ani Pharmaceuticals Announces the Fda Approval and Launch of Estradiol Gel, 0.1%

ANI Pharmaceuticals, Inc. Announces Board Changes

President recently sold €3.0m worth of stock

Second quarter 2023 earnings released: EPS: US$0.30 (vs US$0.94 loss in 2Q 2022)

Forecast breakeven date moved forward to 2023

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023

ANI Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Profitability

ANI Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $75.000033 million.

First quarter 2023 earnings released: EPS: US$0.063 (vs US$1.27 loss in 1Q 2022)

ANI Pharmaceuticals, Inc. Raises Revenue Guidance for Full Year 2023

Full year 2022 earnings released: US$3.05 loss per share (vs US$3.40 loss in FY 2021)

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Levocarnitine Tablets USP

ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Trimethoprim Tablets USP

High number of new directors

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$0.37 loss in 3Q 2021)

Ani Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Year 2022

ANI Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

ANI Pharmaceuticals, Inc. Appoints Krista Davis as Chief Human Resources Officer

ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP

Key Executive recently sold €661k worth of stock

ANI Pharmaceuticals, Inc. Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP

ANI Pharmaceuticals, Inc. Reports Impairment Charge for the Second Quarter Ended June 30, 2022

Second quarter 2022 earnings released: US$0.94 loss per share (vs US$1.17 loss in 2Q 2021)

Ani Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP

ANI Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022

ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary

ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP

ANI Pharmaceuticals, Inc. Provides Revenue Guidance for the Fiscal Year 2022

First quarter 2022 earnings released: US$1.27 loss per share (vs US$0.007 profit in 1Q 2021)

High number of new directors

ANI Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 10, 2022

ANI Pharmaceuticals, Inc. Announces the Launch of Misoprostol Tablets

Chairman recently bought €126k worth of stock